Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of HDM1005 in adults with obstructive sleep apnea and obesity or overweight
CTR20263391Phase 3Active
- Sponsor
- 杭州中美华东制药有限公司 (Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.)
- Start
- Sep 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of poterepatide in obstructive sleep apnea hypopnea syndrome (OSAHS), obesity, Overweight, sponsored by 杭州中美华东制药有限公司 (Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.). Started Sep 2026; status: active.
02
Drugs
poterepatide
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)obesityOverweight
Beyond the preview
Go deeper on CTR20263391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263391.